Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

I have been thinking about this all day and this i

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155120
(Total Views: 572)
Posted On: 10/03/2020 5:16:51 PM
Posted By: invisioner
Re: crazyjogger925 #59501
I have been thinking about this all day and this is just my opinion and speculation.

Yes, remdesivir has potential kidney/liver side effects and if they decided to give it to him aggressively, they would want him to be in a setting where he could receive the best critical care, if needed. Or if anything like clotting started to happen and cardiac stuff.

Trying to be as impartial as I can, I believe there is no reason to disbelieve what his doctor reported this morning.

On the other hand, if he were in bad shape (which doesn't seem likely only 72 hours into the disease) there is a case to be made that they would not report it to the public.

In the event that he is or does move into the severe category, it is my belief that they might give him an unapproved experimental drug in addition to dexamethasone. I think they would only do this if he took a turn for the worse and dexamethosone was not working. It is my belief that leronlimab would be one of four drugs they might consider. They might consider RLF100, leronlimab, lenzilumab, or the oncoimmune drug which just reported trial data.

I don't know of another drug they would consider, but I don't think they are going to even consider it unless the situation becomes dire.

However, I don't think it will become dire because he got the REGN early. (I don't think remdesivir does much, but I think the REGN might help decrease viral load to the point that he can fight it off.) Also he is being handled with kid gloves by an incredible team. So, I am thinking that he will recover without an experimental drug other than the REGN he's been given.

I am sorry I went on and on. I am just trying to figure this out....


(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us